Thermo Fisher Scientific Inc. (TMO) News

Thermo Fisher Scientific Inc. (TMO): $535.11

0.84 (+0.16%)

POWR Rating

Component Grades













Filter TMO News Items

TMO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TMO News Highlights

  • For TMO, its 30 day story count is now at 70.
  • Over the past 23 days, the trend for TMO's stories per day has been choppy and unclear. It has oscillated between 1 and 18.
  • The most mentioned tickers in articles about TMO are MRNA, AMP and BIO.

Latest TMO News From Around the Web

Below are the latest news stories about Thermo Fisher Scientific Inc that investors may wish to consider to help them evaluate TMO as an investment opportunity.

Thermo Fisher (TMO) COVID Test Sales Grow, FX Woes Persist

Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.

Yahoo | February 25, 2022

These 10 Companies Just Increased Their Dividends By Over 10%

In this article, we discuss 10 companies that just increased their dividends by over 10%. If you want to skip our detailed analysis of these stocks, go directly to These 5 Companies Just Increased Their Dividends By Over 10%. The S&P 500 is heading into correction territory as the Russian attack on Ukraine has severely […]

Yahoo | February 25, 2022

Thermo Fisher Rewards Shareholders with 15.4% Dividend Hike

Scientific instrumentation and software services provider Thermo Fisher Scientific Inc. (NYSE: TMO) recently announced a quarterly dividend of $0.30 per share, a 15.4% increase from the previous dividend of $0.26 per share. The dividend will be paid on April 14, 2022, to shareholders of record as of March 16, 2022. The company’s annual dividend of $1.2 per share now reflects a dividend yield of 0.2% based on Wednesday’s closing price. Notably, the company has been raising its dividend consistently over the past four years, making it an attractive choice for investors. Stock Rating Recently, Cowen & Co.analyst Daniel Brennan reiterated a Buy rating on the stock.

Pathikrit Bose on TipRanks | February 24, 2022

Thermo Fisher Scientific: Strong Growth, Relatively Overvalued

Thermo Fisher Scientific, Inc. (TMO) provides analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services segments. I am neutral on TMO stock. Its profitability is consistent and strong, but there is a high level of debt, as the company significantly increased its long-term debt in 2021, and the latest fourth-quarter 2021 results were mixed. Investors looking for dividend stocks most probably will not get excited by the minimal dividend yield of Thermo Fisher Scientific. However, the firm's strong financial performance may still make the stock appealing to investors.

Stavros Georgiadis on TipRanks | February 24, 2022

Triangle's CRO industry saw a flurry of M&A activity over past year

One sign of the ever-evolving life sciences scene in the Triangle: There have been at least a dozen mergers and acquisitions that have involved either a Triangle-owned CRO or one with a major local presence in just the past year.

Yahoo | February 24, 2022

The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.

Yahoo | February 24, 2022

Thermo Fisher Scientific raises dividend by 15% to $0.30/share (NYSE:TMO)

Thermo Fisher Scientific (TMO) declares $0.30/share quarterly dividend, 15% increase from prior dividend of $0.26.

Seeking Alpha | February 23, 2022

Moderna taps Thermo Fisher for long-term production of COVID-19 shot (MRNA)

Moderna (MRNA) and Thermo Fisher Scientific (TMO) have inked a 15-year strategic collaboration agreement. Read more on its details.

Seeking Alpha | February 23, 2022

Moderna, Thermo Fisher Join Forces To Manufacture COVID-19 Vaccine, Other Drugs

Moderna Inc (NASDAQ: MRNA ) has entered into a long-term agreement with Thermo Fisher Scientific Inc (NYSE: TMO ) to manufacture its COVID-19 vaccine and other experimental medicines based on mRNA technology. Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, … Full story available on

Benzinga | February 23, 2022

Moderna, Thermo Fisher partner to manufacture COVID vaccine, other drugs

Moderna Inc has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its COVID-19 vaccine and other experimental medicines based on mRNA technology, the companies said on Wednesday.

Reuters | February 23, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.622 seconds.